Köhler U, Hiller K, Martin R, Langanke D, Naumann G, Bilek K, Jänicke F, Schmitt M
Universitäts-Frauenklinik, Leipzig, Germany.
Gynecol Oncol. 1997 Aug;66(2):268-74. doi: 10.1006/gyno.1997.4751.
The levels of plasminogen activator urokinase (uPA) and of its inhibitor (PAI-1) were measured by use of ELISA in the cytosol of tissue homogenates obtained from endometrial carcinomas and the marginal, tumor-free endometrium of postmenopausal patients (n = 64). Significantly higher median levels of uPA and PAI-1 were found in malignant endometrium (uPA 1.89 ng/mg, PAI-1 3.04 ng/mg) compared to tumor-free endometrium (uPA 0.84 ng/mg, PAI-1 1.01 ng/mg). Concerning uPA, no significant differences were found in dependence on histomorphological prognostic factors (staging, grading), but the median level of PAI-1 was significantly higher in G2/G3 carcinomas compared to G1 tumors (5.08 ng/mg vs 2.19 ng/mg). Because of the good prognosis of operated patients with endometrial carcinomas, the prognostic value of uPA and PAI-1 can only be decided by a larger number of patients and a long observation time.
采用酶联免疫吸附测定法（ELISA），检测了64例绝经后子宫内膜癌患者及肿瘤边缘无瘤子宫内膜组织匀浆细胞溶质中纤溶酶原激活物尿激酶（uPA）及其抑制剂（PAI - 1）的水平。结果发现，恶性子宫内膜中uPA和PAI - 1的中位数水平（uPA 1.89 ng/mg，PAI - 1 3.04 ng/mg）显著高于无瘤子宫内膜（uPA 0.84 ng/mg，PAI - 1 1.01 ng/mg）。关于uPA，未发现其水平在组织形态学预后因素（分期、分级）方面存在显著差异，但G2/G3期癌组织中PAI - 1的中位数水平显著高于G1期肿瘤（分别为5.08 ng/mg和2.19 ng/mg）。鉴于接受手术治疗的子宫内膜癌患者预后良好，uPA和PAI - 1的预后价值只能通过更多患者及更长观察时间来确定。
